newsfilter
← Latest News
GlobeNewswire·

Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Announced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients; plan to submit a New Drug Application (NDA) to the FDA in mid-2022 Development of DYRK1A inh